Kyntra Bio Inc (NASDAQ:KYNB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been given an average recommendation of “Moderate Buy” by the five research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $32.50.

Several analysts recently weighed in on KYNB shares. Weiss Ratings reissued a “sell (d)” rating on shares of Kyntra Bio in a report on Tuesday, June 16th. Wall Street Zen upgraded Kyntra Bio from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Rodman & Renshaw initiated coverage on Kyntra Bio in a report on Tuesday, June 9th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Oppenheimer started coverage on Kyntra Bio in a research report on Monday. They set an “outperform” rating and a $35.00 price target on the stock.

Kyntra Bio Price Performance

KYNB opened at $7.61 on Monday. The company has a market cap of $30.82 million, a P/E ratio of 0.19 and a beta of 0.96. The business has a 50-day moving average of $7.03. Kyntra Bio has a 1-year low of $6.32 and a 1-year high of $12.60.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Kyntra Bio stock. Renaissance Technologies LLC acquired a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned about 0.68% of Kyntra Bio as of its most recent SEC filing. Institutional investors and hedge funds own 72.71% of the company’s stock.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.